Quanterix Corp 8K

Quanterix Corporation reported Q2 2026 results, took a $26.9 million goodwill impairment, launched new products and secured Alzheimer’s test coverage, and materially lowered its 2026 revenue and cash-flow outlook while pushing cash-flow breakeven to 2027.

On August 10, 2026, Quanterix Corporation reported its second quarter 2026 financial results, highlighting $32.9 million in revenue (up 34% year-over-year), a GAAP gross margin of 38.5%, an adjusted EBITDA loss of $10.0 million, and quarter-end liquidity of $96.9 million in cash and marketable securities, while also recording a $26.9 million goodwill impairment related to its Akoya acquisition, completing the ERP integration tied to that deal with $85 million annualized savings, finishing a rebuild of its senior management team, announcing expanded commercial insurance coverage and new clinical data for its Lucent AD blood-based Alzheimer’s test, launching multiple new biomarker and spatial products, securing a multi-year Parkinson’s research grant role, and revising its 2026 outlook to lower expected revenues ($142–148 million vs. $169–174 million prior), slightly lower projected non-GAAP gross margins, a reduced year-end cash balance (~$80 million vs. $100 million previously), and a later target for achieving cash-flow breakeven (now 2027).

Filing Facts

CIK

1503274

Ticker

-

Form

8K

Source Type

sec

Accession

0001503274-26-000035

Alert Tier

7